Skip to content use cookies to help us improve the website and your experience using it. You may delete and block all cookies from this site at any time, details of which can be found in our cookie policy. However please note this may result in parts of the site no longer working correctly. If you continue without changing your settings we will assume you are happy to receive all cookies on this site.

Pharmbiotest took part in the international congress in Rome

27 December 2022


Pharmbiotest representatives took part in the congress of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT 2021) held in Rome at the end of September.

IATDMCT is an organization founded by an international group of scholars and doctors with the aim of communication on the topic of therapeutic drug monitoring and clinical toxicology around the world.

The congress was attended by specialists from medical universities, laboratories and hospitals from USA, Italy, Australia, Germany, China, Belgium and France.

The congress program included 9 round table sessions with a special focus on pharmacology and therapeutic drug monitoring (TDM), pharmacogenetics, pharmacometrics, TDM in oncology, TDM of biopharmaceuticals, nanotechnologies and nanomedicine. At the session dedicated to clinical toxicology the issues of drug abuse in clinical toxicology and environmental hygiene have been discussed.

At this event representatives of Pharmbiotest presented their experience in bioequivalence study of Favipiravir – Microkhim, which is the first generic drug against SARS-CoV-2 registered in Ukraine.

It is noteworthy that in September last year Fujifilm Toyama Chemical, Japan, has conducted clinical trials, which results proven the efficiency of Avigan (Favipiravir) against the disease evoked by corona virus infection. In April 2020 the original drug was entered into the list of drugs preventing the spread of corona virus in Ukraine. The Ukrainian pharmaceutical company Microkhim decided to produce a generic drug. At the peak of the pandemics all necessary studies had been carried out in the laboratory of Pharmbiotest, which had proven that the drug complies with all the standards and protocols of the Ministry of Healthcare of Ukraine. Hence, Ukrainians got the access to the affordable drug that affects the pathogenesis of corona virus.

Owing to its participation in this congress, Pharmbiotest also got the possibility to familiarize itself with experience of its foreign colleagues and consider the proposals of implementing innovative methods into the company’s routine since efficient implementation of developments of the world leaders in the medical industry is one of the major pillars of our strategy.

As a result of the event, Pharmbiotest got interesting offers and concluded agreements of further cooperation with a number of foreign medical companies and contract research organizations

Scroll To Top